{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LCC&page=12", "query": { "condition": "LCC", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 1039, "total_pages": 104, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LCC&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LCC&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T07:33:58.863Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00627042", "title": "Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Ramucirumab (IMC-1121B)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2008-02", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2014-10-08", "last_synced_at": "2026-10-22T07:33:58.863Z", "location_count": 6, "location_summary": "Los Angeles, California • Chicago, Illinois • Metairie, Louisiana + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Burlington", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00627042" }, { "nct_id": "NCT02702960", "title": "Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fibrolamellar Hepatocellular Carcinoma", "Hepatocellular Carcinoma (Fibrolamellar Variant)", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "living related donor partial liver transplantation", "type": "PROCEDURE" }, { "name": "Total body irradiation", "type": "RADIATION" }, { "name": "Bone marrow transplant from same donor", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Antithymocyte globulin", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "16 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2016-03", "completion_date": "2018-01-03", "has_results": false, "last_update_posted_date": "2018-06-15", "last_synced_at": "2026-10-22T07:33:58.863Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02702960" }, { "nct_id": "NCT00257426", "title": "Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "octreotide acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2005-07", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2012-02-14", "last_synced_at": "2026-10-22T07:33:58.863Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00257426" }, { "nct_id": "NCT03222076", "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma", "Resectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2017-09-28", "completion_date": "2022-09-14", "has_results": true, "last_update_posted_date": "2023-07-10", "last_synced_at": "2026-10-22T07:33:58.863Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03222076" }, { "nct_id": "NCT01498952", "title": "MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unresectable or Metastatic Hepatocellular Carcinoma (HCC)" ], "interventions": [ { "name": "MEDI-573 (1 of 3 doses)", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 6, "start_date": "2012-01-17", "completion_date": "2013-04-09", "has_results": true, "last_update_posted_date": "2019-02-19", "last_synced_at": "2026-10-22T07:33:58.863Z", "location_count": 3, "location_summary": "Oxnard, California • Golden Springs, Colorado • Las Vegas, Nevada", "locations": [ { "city": "Oxnard", "state": "California" }, { "city": "Golden Springs", "state": "Colorado" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT01498952" }, { "nct_id": "NCT02460991", "title": "A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma", "Hepatoma", "Liver Cell Carcinoma" ], "interventions": [ { "name": "DEB-TACE", "type": "DEVICE" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Boston Scientific Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2015-11", "completion_date": "2017-06-05", "has_results": true, "last_update_posted_date": "2021-02-12", "last_synced_at": "2026-10-22T07:33:58.863Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Los Angeles, California • Louisville, Kentucky + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02460991" }, { "nct_id": "NCT01774344", "title": "Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "Regorafenib (Stivarga, BAY73-4506)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 573, "start_date": "2013-05-14", "completion_date": "2019-07-05", "has_results": true, "last_update_posted_date": "2020-08-20", "last_synced_at": "2026-10-22T07:33:58.863Z", "location_count": 17, "location_summary": "Los Angeles, California • Orange, California • Aurora, Colorado + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01774344" }, { "nct_id": "NCT00867321", "title": "Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "sorafenib tosylate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 24, "start_date": "2009-04", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2022-04-19", "last_synced_at": "2026-10-22T07:33:58.863Z", "location_count": 177, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 113 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00867321" }, { "nct_id": "NCT00293436", "title": "Celecoxib and Erlotinib in Treating Patients With Liver Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "celecoxib", "type": "DRUG" }, { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2005-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-09-17", "last_synced_at": "2026-10-22T07:33:58.863Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00293436" }, { "nct_id": "NCT00076609", "title": "Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma", "Liver Cancer" ], "interventions": [ { "name": "PHY906", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PhytoCeutica", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 31, "start_date": "2003-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2007-03-28", "last_synced_at": "2026-10-22T07:33:58.863Z", "location_count": 4, "location_summary": "Duarte, California • Stanford, California • New Haven, Connecticut + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "West Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00076609" } ] }